Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06388200 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

Study acronym: liMeliGhT
StatusActive, Not Recruiting
PhasePhase 3
SponsorOcugen
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv14
  2. Primary endpoints: 2 to 1v13 Show 4 more changesShow less
    • Enrollment target: estimated 150 to confirmed 140
    • Primary and study completion dates: Dec 31, 2026 to Feb 12, 2027
    • Secondary endpoints: 5 to 4
    • Study description shortened, about 6 words
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 17 of 17 sites
    v12
  4. Eligibility criteria revisedv11
  5. Site details revised at 1 of 17 sitesv10
Show 8 earlier versionsHide 8 earlier versions
  1. Primary completion date: Jun 30, 2025 to Dec 31, 2026
    • Study sites: 16 to 17
    • Study completion date: Oct 30, 2026 to Dec 31, 2026
    v9
  2. Study sites: 15 to 16
    • Eligibility criteria expanded, about 2 words
    v8
  3. Site details revised at 1 of 15 sitesv7
  4. Site contacts updated at 1 of 15 sitesv6
  5. Site details revised at 5 of 15 sitesv5
  6. Site contacts updated at 1 of 15 sitesv4
  7. Study sites: 5 to 15v3
  8. Study sites: 2 to 5
    • Start date changed from estimate of Apr 26, 2024 to Jun 18, 2024
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Ocugen
6 trials monitored
See all monitored trials
This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mutation with a clinical phenotype of RP. This is a multicenter, assessor blinded and randomized study which will enroll 140 subjects. Study has completed enrollment of all 140 subjects.
Trial Details
NCT Number NCT06388200
Lead Sponsor Ocugen
Conditions
(from sponsor)		 Retinitis Pigmentosa
Related terms Retinitis Pigmentosa
Enrollment 140 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov